Last reviewed · How we verify
Bladder instillation WITH triamcinolone acetonide
Triamcinolone acetonide delivered directly into the bladder reduces inflammation and suppresses local immune responses in bladder tissue.
Triamcinolone acetonide delivered directly into the bladder reduces inflammation and suppresses local immune responses in bladder tissue. Used for Interstitial cystitis/bladder pain syndrome, Bladder inflammation or cystitis.
At a glance
| Generic name | Bladder instillation WITH triamcinolone acetonide |
|---|---|
| Sponsor | Olivia Cardenas-Trowers, M.D. |
| Drug class | Corticosteroid (intravesical instillation) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Urology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Triamcinolone acetonide is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects when instilled directly into the bladder. By local delivery, it reduces inflammatory cytokine production, decreases immune cell infiltration, and suppresses aberrant bladder mucosa responses. This localized approach minimizes systemic steroid exposure while targeting bladder-specific pathology.
Approved indications
- Interstitial cystitis/bladder pain syndrome
- Bladder inflammation or cystitis
Common side effects
- Dysuria
- Urinary frequency
- Hematuria
- Local bladder irritation
- Urinary tract infection
Key clinical trials
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC (PHASE4)
- Clinical Trial Comparing Two Bladder Instillations for IC/BPS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: